Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00183937
Status:
COMPLETED
Last Update Posted:
2018-05-14
First Post:
2005-09-09
Brief Title:
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
Sponsor:
University of Southern California
Organization:
University of Southern California
Study Overview
Official Title:
A Phase II Study of Bortezomib Velcade PS-341 and Docetaxel for Patients With Hormone Refractory Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is for patients who have been treated with surgical removal of the testes or hormone therapy Lupron or Zoladex and whose prostate cancer has worsened despite this treatment
PS 341 is a type of drug known as a proteasome inhibitor By inhibiting the proteasome in cancer cells PS-341 alters the way those cells divide We hope to learn whether this combination chemotherapy decreases cancer symptoms and tests prostate specific antigen also called PSA and to determine how frequently serious side effects might occur with this treatment for this stage of prostate cancer
PS 341 is a type of drug known as a proteasome inhibitor By inhibiting the proteasome in cancer cells PS-341 alters the way those cells divide We hope to learn whether this combination chemotherapy decreases cancer symptoms and tests prostate specific antigen also called PSA and to determine how frequently serious side effects might occur with this treatment for this stage of prostate cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None